Telix Pharmaceuticals reports $7.5m net loss in 2025
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals reported a net loss of USD5.3 million ($7.5 million) for the year ended 31 December 2025, down from a USD38 million profit a year ago, citing non-cash finance costs associated with convertible bonds and increased amortisation of USD11.9 million following the RLS Radiopharmacies acquisition.
The numbers: The biopharmaceuticals group posted a 56% increase in full-year revenue to USD803.8 million.
Adjusted earnings before interest and tax came in at USD39.5 million, driven by increased spending on acquisitions and research and development projects, while the year-end cash balance stood at USD141.9 million.
The company did not declare a dividend.
The context: Telix Pharmaceuticals’ group CEO Christian Behrenbruch said the company plans to reinvest its earnings to priorities the advancement of prostate, kidney and brain cancer programs. He added that it plans to expand precision medicine growth opportunities through label expansion studies and new product launches.
Telix forecasts FY26 group revenue to be between USD950 million to USD970 million, with pipeline research and development project spending of USD200 million to USD240million.
The source: ASX
